Search by Drug Name or NDC

    NDC 00078-0937-91 EGATEN 250 mg/1 Details

    EGATEN 250 mg/1

    EGATEN is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is TRICLABENDAZOLE.

    Product Information

    NDC 00078-0937
    Product ID 0078-0937_9883f3fe-4881-47cc-a795-ce9245fe0645
    Associated GPIs 15000093000320
    GCN Sequence Number 059673
    GCN Sequence Number Description triclabendazole TABLET 250 MG ORAL
    HIC3 W4L
    HIC3 Description ANTHELMINTICS
    GCN 25419
    HICL Sequence Number 033198
    HICL Sequence Number Description TRICLABENDAZOLE
    Brand/Generic Brand
    Proprietary Name EGATEN
    Proprietary Name Suffix n/a
    Non-Proprietary Name triclabendazole
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET
    Route ORAL
    Active Ingredient Strength 250
    Active Ingredient Units mg/1
    Substance Name TRICLABENDAZOLE
    Labeler Name Novartis Pharmaceuticals Corporation
    Pharmaceutical Class Anthelmintic [EPC], Anthelmintics [CS], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2A6 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2C9 Inhi
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA208711
    Listing Certified Through 2024-12-31

    Package

    NDC 00078-0937-91 (00078093791)

    NDC Package Code 0078-0937-91
    Billing NDC 00078093791
    Package 4 TABLET in 1 BLISTER PACK (0078-0937-91)
    Marketing Start Date 2019-02-13
    NDC Exclude Flag N
    Pricing Information N/A